Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Study to Evaluate the Safety of FURESTEM-RA Inj. in Moderate to Severe Rheumatoid Arthritis Patients Who Participated in Phase 1 Clinical Trial of FURESTEM-RA Inj

NCT03106259 is registered in ClinicalTrials.gov with Kang Stem Biotech Co., Ltd. as lead sponsor.

NCT NCT03106259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03106259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Study to Evaluate the Safety of FURESTEM-RA Inj. in Moderate to Severe Rheumatoid Arthritis Patients Who Participated in Phase 1 Clinical Trial of FURESTEM-RA Inj
Lead sponsor
Kang Stem Biotech Co., Ltd.
Phase
Observational
Overall status
Unknown status
Start date
June 29, 2016
Completion date
March 21, 2021
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis